Trials / Completed
CompletedNCT05633108
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
A Retrospective Observational Study Based on the French National Health Insurance Database to Describe Antipsychotic Monotherapy and Polypharmacy Use, Including Loxapac, and to Investigate Their Association With Psychiatric Rehospitalization in Patients With Psychotic Disorders
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 579,728 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic combination, regarding time to psychiatric rehospitalization, in participants with a psychotic disorder (that is, schizophrenia, schizotypal disorders, schizoaffective disorders, persistent or acute or induced or non-organic delusional disorders, recurrent depressive disorder with psychotic symptoms).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | No intervention will be administered. |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2022-12-01
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05633108. Inclusion in this directory is not an endorsement.